GLP-1 · RTR-001

RETATRUTIDE

The triple-agonist apex.

Triple-receptor agonist (GLP-1, GIP, glucagon) representing the new frontier of metabolic peptide therapy.

Protocol

2–12mg weekly

Investment

40mg £85 , PEN £120

Expected Outcomes

What the molecule delivers.

Unmatched fat reduction

Improved insulin sensitivity

Enhanced thermogenesis

Dual-agonist metabolic recalibration.